Clinical trial data published in The American Journal of Psychiatry suggests patients who suffer from schizophrenia could manage their psychotic symptoms better through the addition of CBD therapy on a daily basis. In the randomized trial, British researchers compared the addition of 1000 mg of CBD to the addition of placebo in 88 patients’ conventional therapy regimens over the course of six weeks. At the end of the trial, researchers say those who received CBD “had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician.” CBD also improved cognitive performance and overall functioning in patients, but these results were not significant statistically. Authors conclude, “These findings suggest that CBD has beneficial effects in patients with schizophrenia… As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”
This information has been provided by the Daily Chronic and approved by our Chief Medical Officer.